Evidence map›Paper›PMID 33587887›Full record

ReviewLancet (London, England)2021

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.

Olivier J Wouters, Kenneth C Shadlen, Maximilian Salcher-Konrad, Andrew J Pollard, Heidi J Larson, Yot Teerawattananon, Mark Jit

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 644 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
644citing papers in PubMed, 8 pooled it
146.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

644 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,328 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

584 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Olivier J WoutersDepartment of Health Policy, London School of Economics and Political Science, London, UK. Electronic address: o.j.wouters@lse.ac.uk.
Kenneth C ShadlenDepartment of International Development, London School of Economics and Political Science, London, UK.
Maximilian Salcher-KonradDepartment of Health Policy, London School of Economics and Political Science, London, UK.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
Heidi J LarsonDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Department of Health Metrics Sciences, University of Washington, Seattle, WA, USA.
Yot TeerawattananonHealth Intervention and Technology Assessment Program, Ministry of Public Health, Thailand; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Mark JitDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
London School of Economics and Political Science · GBLondon School of Hygiene & Tropical Medicine · GBHealth Intervention and Technology Assessment Program · THUniversity of Oxford · GB

Funding

Medical Research Council MC_PC_19055
6 · The paper itself

Abstract

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities. In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. Although specific datapoints are subject to change as the pandemic response progresses, the dashboard will continue to provide a useful lens through which to analyse the key issues affecting the use of COVID-19 vaccines. We also present original data from a 32-country survey (n=26 758) on potential acceptance of COVID-19 vaccines, conducted from October to December, 2020. Vaccine acceptance was highest in Vietnam (98%), India (91%), China (91%), Denmark (87%), and South Korea (87%), and lowest in Serbia (38%), Croatia (41%), France (44%), Lebanon (44%), and Paraguay (51%).

Indexed as

Drug DevelopmentImmunization ProgramsCOVID-19COVID-19 VaccinesGlobal HealthHealth Services AccessibilityHumansInternational CooperationPatient Acceptance of Health CareResource AllocationCOVID-19 Vaccines

Identifiers

PMID33587887
PMCPMC7906643
OpenAlexW3131672727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.